Principal Financial Group Inc. Grows Stake in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Principal Financial Group Inc. increased its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 5.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 423,432 shares of the life sciences company's stock after buying an additional 22,000 shares during the period. Principal Financial Group Inc. owned 0.55% of Integra LifeSciences worth $9,603,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. KBC Group NV grew its holdings in Integra LifeSciences by 65.2% in the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company's stock worth $52,000 after purchasing an additional 1,120 shares during the period. New York State Teachers Retirement System grew its stake in shares of Integra LifeSciences by 3.0% in the 3rd quarter. New York State Teachers Retirement System now owns 90,098 shares of the life sciences company's stock valued at $1,637,000 after buying an additional 2,616 shares during the period. Nisa Investment Advisors LLC increased its position in Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after buying an additional 2,800 shares in the last quarter. Nordea Investment Management AB raised its stake in Integra LifeSciences by 4.1% during the 4th quarter. Nordea Investment Management AB now owns 127,908 shares of the life sciences company's stock worth $2,919,000 after buying an additional 5,032 shares during the period. Finally, Choreo LLC boosted its holdings in Integra LifeSciences by 29.9% in the fourth quarter. Choreo LLC now owns 22,274 shares of the life sciences company's stock worth $500,000 after acquiring an additional 5,123 shares in the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Stock Down 3.1 %

Integra LifeSciences stock traded down $0.73 during trading on Monday, hitting $22.48. 1,864,123 shares of the company were exchanged, compared to its average volume of 649,588. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The company has a market capitalization of $1.74 billion, a P/E ratio of -249.75, a PEG ratio of 0.73 and a beta of 1.17. The business's 50 day moving average is $23.80 and its 200 day moving average is $21.87. Integra LifeSciences Holdings Co. has a 52 week low of $16.81 and a 52 week high of $37.17.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $442.65 million for the quarter, compared to the consensus estimate of $445.15 million. During the same quarter in the previous year, the business earned $0.89 EPS. The company's revenue was up 11.5% compared to the same quarter last year. Analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IART has been the topic of a number of research reports. Citigroup upped their target price on Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a research report on Tuesday, November 5th. Morgan Stanley began coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They set an "underweight" rating and a $20.00 price target for the company. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company's stock. According to MarketBeat, Integra LifeSciences currently has an average rating of "Hold" and an average price target of $23.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.